Sign in

CIK 0000908259

  • Non-accelerated filer
  • Smaller reporting company

Oncotelic Therapeutics, Inc.

Sign in to watch
Ticker
OTLC
Exchange
OTC
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
133679168
Phone
+1 650-635-7000
Business address
29397 AGOURA RD., #107, AGUORA HILLS, CA, 91301
Former names
MATEON THERAPEUTICS INC, OXIGENE INC
  1. 4 Grant or award Director acquired 40,000 shares (grant or award)
  2. 3 Insider Initial Statement of Ownership
  3. 3 Insider Initial Statement of Ownership
  4. 4 Open-market buy Director bought 25,000 shares at an average $4.58 ($114,403)
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Grant or award President and CEO acquired 250,000 shares (grant or award)
  11. 4 Open-market buy Director bought 65,800 shares at $4.94 ($325,052)
  12. 4 Open-market buy Director bought 100,000 shares at $5.02 ($502,000)
  13. 4 Open-market buy Director bought 15,000 shares at an average $4.27 ($64,024)
  14. 4 Returned to the company Director returned 20,000 shares (to the company)
  15. 4 Open-market buy President and CEO bought 45,464 shares at an average $4.09 ($185,837)
  16. 4 Open-market buy Director bought 84,200 shares at an average $3.49 ($294,146)
  17. 4 Open-market buy Director bought 12,403 shares at $3.23 ($40,062)
  18. 4 Open-market buy President and CEO bought 20,000 shares at an average $3.30 ($65,950)
  19. 4 Open-market buy Director bought 47,597 shares at an average $3.22 ($153,368)
  20. 4 Open-market buy Director bought 50,000 shares at $3.07 ($153,715)

Page 11 of 17 · 325 filings